Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib in KRAS G12C-mutant NSCLC (breakthrough)
NCT05451056Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Aug 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05451056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451056.